Data from a collaborative study between the University Hospital Basel (UHB) and MindMed supports the clinical development of MindMed’s proprietary MM-120 product candidate – a pharmacologically...
Results from a small study suggest that low-dose ketamine could be an effective treatment for children living with ADNP syndrome, otherwise known as Helsmoortel-VanDerAa syndrome.
Cybin has now dosed the first patients in its Phase 1/2a trial clinical trial investigating in psilocybin analogue CYB003 for the treatment of major depressive disorder...
Heroic Hearts Project and Maya PBC are partnering to generate the largest structured dataset illustrating the health outcomes of psychedelic treatments for veterans and their family...
New study findings have shown that mice respond more to the antidepressant effects of the drug ketamine when administered by men and not by women.
A study by researchers at NYU Grossman School of Medicine has found that two doses of psilocybin reduced heavy drinking by 83 per cent when combined...
A new study by Johns Hopkins Medicine researchers compared psychedelic experiences with near-death experiences that were not drug-related, finding notable similarities in people’s attitudes toward death.
Awakn Life Sciences has signed the twelve month option agreement with a drug development company that will see its ketamine formulation and route of administration optimised...
Biopharmaceutical company MindMed has dosed the first patient in its Phase 2b Trial of its pharmaceutically optimised form of LSD – MM-120 – in GAD.
Unlimited Sciences, a psychedelic research nonprofit, will be carrying out an observational research study that will measure the potential healing effects of Ayahuasca on individuals with...